Brief: Entera Bio And Opko Health Provide Update On Pk/Pd Results Of Oral Oxyntomodulin (Glp-1/Glucagon) Peptide Tablet Candidate For Obesity And Metabolic Disorders
25/09/2024 13:41
Sept 25 (Reuters) - Entera Bio Ltd 5DT.F :
* ENTERA BIO AND OPKO HEALTH PROVIDE UPDATE ON PK/PD RESULTS
OF
ORAL OXYNTOMODULIN (GLP-1/GLUCAGON) PEPTIDE TABLET CANDIDATE FOR
OBESITY AND METABOLIC DISORDERS
* ENTERA BIO LTD - ORAL OXM REDUCED PLASMA GLUCOSE LEVELS
SIGNIFICANTLY
Source text for Eikon: ID:nGNX5r8csW
Further company coverage: 5DT.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OPKO Health
See all newsOpko Health, Inc. Expected To Post A Loss Of 7 Cents A Share: Earnings Preview
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
US RESEARCH ROUNDUP-Bank7, Goldman Sachs, Morgan Stanley
Deals of the day-Mergers and acquisitions
US STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons